Related-Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party TransactionsFor the three and nine months ended September 30, 2023, the Company had revenue of $0 and $0.8 million, respectively, from Pharmaceutical Product Development, LLC (“PPD”), a wholly-owned subsidiary of Thermo Fisher Scientific, Inc. and a shareholder who beneficially owns 5% or more of the Company’s common stock. For the three and nine months ended September 30, 2022, the Company had revenue of $1.1 million and $5.4 million, respectively, from PPD. In addition, as of September 30, 2023 and December 31, 2022, the Company had receivables of $0.2 million and $0.7 million, respectively, from PPD.